<DOC>
	<DOCNO>NCT02670226</DOCNO>
	<brief_summary>The first objective find biomarkers , profile biomarkers ALS help diagnosis . The second objective good understand pathogenesis disease exploration muscle , blood satellite cell metabolomes transcriptomes .</brief_summary>
	<brief_title>Muscular Biomarkers Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic Lateral Sclerosis ( ALS ) , common MND , fatal adult-onset neuromuscular disease . Due clinical heterogeneity absence biological tool diagnose ALS , delay first symptoms diagnosis average 9-13 month . A group pathophysiological process , include oxidative stress glutamate-mediated excitotoxicity contribute cell death , trigger factor , time interaction different cellular event await elucidation [ 2 ] . Unknown pathogenesis patient mean available treatment . The search biomarkers aid diagnosis , characterize phenotype , define pathophysiology , identify endpoint trial measure disease progression utmost importance field . Some study advocate muscle per se may impair pathogenesis disease . Muscle poorly study central role energetic metabolism suggest tissue , quite easily available , analyzed find biomarkers compare muscular metabolism brain overall body . Specific aims subject : Specific aim focus : 1. acquisition metabolite profile muscle , blood satellite cell use analytical platform enable deep exploration . For , use three analytical modality ( NMR , mass spectrometry couple GC UPLC ) ensure best coverage metabolite population high range concentration variability molecular diversity . 2. building metabolite profile model discriminate pathological control situation . 3. identification metabolite implicate discriminant model . 4. generation metabolism pathway hypothesis relate discriminant model . 5. acquisition transcriptomics data confirm add complementary result metabolomics data</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Case group selection criterion : Age ≥ 18 year ≥ 75 year ALS accord El Escorial criterion Patients affiliate social security scheme Informed consent sign patient Pregnant breastfeed woman Contraindication biopsy Contraindication local anesthesia Treatment oral injectable anticoagulant , antiplatelet ( except aspirin ) Unbalanced Diabetes Systemic corticosteroid treatment Treatment cramp twitch may affect muscle metabolism Control group selection criterion : Age ≥ 18 year ≥ 75 year No neuronal disease Patients affiliate social security scheme Informed consent sign patient Pregnant breastfeed woman Contraindication biopsy Treatment oral injectable anticoagulant , antiplatelet ( except aspirin ) Unbalanced Diabetes Systemic corticosteroid treatment Treatment cramp twitch may affect muscle metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Muscle metabolism</keyword>
	<keyword>Metabolomics</keyword>
	<keyword>Transcriptomics</keyword>
</DOC>